t
Oxford Biomedica PLC (OXB) announced the admission of 122,901 new ordinary shares of 50p each to trading on the Main Market of the London Stock Exchange on June 22, 2026. These shares were allotted under OXB's Long Term Incentive Plan, Deferred Bonus Plan, Sharesave Scheme, and Employee Share Option Scheme, for the period between April 24, 2026, and June 11, 2026. Following this admission, the total number of shares admitted to trading for OXB is 121,037,141.
OXB
Admission to Trading
In accordance with the Financial Conduct Authority's Prospectus Rules: Admission to Trading on a Regulated Market (PRM) sourcebook 1.6.4R, OXB notifies the market that following shares have been admitted to trading pursuant to their allotment under the OXB Long Term Incentive Plan (LTIP), OXB Deferred Bonus Plan (DBP), OXB Sharesave Scheme (SAYE), OXB Employee Share Option Scheme (ESOS) as follows:
|
Issuer name:
|
OXFORD BIOMEDICA PLC |
|
Issuer LEI:
|
213800S1GVQNXQ15K851 |
|
Regulated market on which the shares have been admitted to trading:
|
Main Market for listed securities of the London Stock Exchange |
|
Name, type and ISIN of the shares:
|
Ordinary shares of 50p each GB00BDFBVT43 |
|
Number of further shares admitted to trading covered by the notification:
|
122,901 |
|
Total number of shares admitted to trading (including the new shares):
|
121,037,141 |
|
Confirmation that the new shares are fungible with existing shares already admitted to trading:
|
Confirmed |
|
Date range covered by the notification:
|
24 April 2026 - 11 June 2026 |
-Ends-
Enquiries:
OXB:
Natalie Walter, Chief Legal Officer and Group Company Secretary
T: +44 (0) 1865 783 000 / E: [email protected]
About OXB
OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life changing therapies to patients around the world.
One of the original pioneers in cell and gene therapy, OXB has 30 years of experience in viral vectors; the driving force behind the majority of cell and gene therapies. OXB collaborates with some of the world's most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. OXB's world-class capabilities range from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.
OXB offers a vast number of technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the TetraVecta™ system), a dual-plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines.
OXB, a FTSE250 and FTSE4Good constituent, is headquartered in Oxford, UK. It has development and manufacturing facilities across Oxfordshire, UK, Lyon and Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube.